Building on the MAS-Seq Concatenation
Method, These Three New Kits can Significantly Increase Throughput
in RNA Applications
MENLO
PARK, Calif., Oct. 31,
2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a
leading developer of high-quality, highly accurate sequencing
solutions, today announced it has begun taking orders for its
groundbreaking Kinnex RNA kits, which increase throughput for
full-length RNA, single-cell RNA, and 16S rRNA sequencing on
PacBio's long-read sequencing systems to enable large-scale studies
at a resolution difficult to attain with short-read RNA
sequencing.
"The new family of Kinnex kits for RNA sequencing are designed
to provide customers with cost-effective, end-to-end kitted
solutions to support their research," said Christian Henry, President and Chief Executive
Officer of PacBio. "The Revio system brought scale to HiFi whole
genome sequencing. Our customers have asked for the same for RNA
sequencing, and these Kinnex kits deliver just that with tens of
millions of full-length reads per run. It's a game changer for the
RNA sequencing market."
The Kinnex kits are based on the MAS-Seq method, which
concatenates smaller DNA fragments into longer, HiFi-ready
libraries. Short-read sequencing has difficulty covering entire
transcripts, while long-read sequencing of one transcript would
traditionally result in unused sequencing capacity. With Kinnex,
customers can concatenate transcripts into long libraries for HiFi
sequencing, increasing throughput and making long-read RNA
sequencing more cost effective.
The new Kinnex single-cell RNA kit builds on the existing
MAS-Seq for Single Cell 3' kit, adding additional support of the
10x Genomics 5' kit and library multiplexing.
The Kinnex full-length RNA kit offers full-length RNA sequencing
with abundant information and flexible sample multiplexing. The kit
can yield 40 million reads on the Revio system per 25M SMRT cell and 15 million reads on the Sequel
II and IIe systems per 8M SMRT cell.
Additionally, the end-to-end workflow includes access to PacBio's
SMRT Link software for full-length RNA and isoform data
analysis.
"The Kinnex kits now allow us to generate HiFi long-read
transcriptome data at a much higher throughput than its predecessor
Iso-Seq and do it at the single-cell level. This is going to be
very useful for more accurately annotating genic regions relative
to short reads in our genome assemblies, and to measure their
expression levels at the single-cell resolution," said Erich
Jarvis, Chair of the Vertebrate Genomes Project and Director the
Vertebrate Genome Lab.
Finally, the Kinnex 16S rRNA kit enables extraordinary
resolution, higher quality microbiome sequencing at any scale. The
kit will yield 60 million reads on the Revio system per
25M SMRT cell and 25 million reads on
Sequel II and IIe systems per 8M SMRT
cell. With a recommendation of 384-plex per library, this new kit
will allow full-length 16S rRNA sequencing at a competitive
per-sample cost relative to current standard short read
sequencing.
"We're excited about the opportunity to drive real advances in
microbiome studies and translational research for our customers
with Kinnex 16S rRNA kit," said Dr. Shuiquan Tang, Director of
Microbiome at Zymo Research. "Having the capability to do
full-length 16S sequencing on PacBio systems allows us to deliver
higher resolution, species level taxonomic data to our customers at
a price that is competitive to short read sequencing."
With the Kinnex kit offerings, Revio will provide customers with
the ability to sequence up to 5,200 RNA samples per year for less
than $500 USD per sample – a 16-fold
throughput increase in number of samples from what was previously
available for PacBio RNA users on the Sequel II and IIe systems.
All three Kinnex kits sell for $5,700
USD each at 12 reactions.
PacBio is now accepting orders for each kit and will begin
shipments in December 2023.
About PacBio
PacBio (NASDAQ: PACB) is a premier life
science technology company that is designing, developing and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technologies stem from two highly differentiated core
technologies focused on accuracy, quality and completeness which
include our HiFi long-read sequencing and our SBB® short-read
sequencing technologies. Our products address solutions across a
broad set of research applications including human germline
sequencing, plant and animal sciences, infectious disease and
microbiology, oncology, and other emerging applications. For more
information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use
Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and the U.S.
Private Securities Litigation Reform Act of 1995. All statements
other than statements of historical fact are forward-looking
statements, including statements relating to the uses, accuracy,
resolution, throughput, third-party compatibility, coverage, cost
advantages, first shipment dates, quality or performance of, or
benefits or expected benefits of using, PacBio products or
technologies. Reported results and orders for any instrument system
should not be considered an indication of future performance. You
should not place undue reliance on forward-looking statements
because they are subject to assumptions, risks, and uncertainties
and could cause actual outcomes and results to differ materially
from currently anticipated results, including, challenges inherent
in developing, manufacturing, launching, marketing and selling new
products; rapidly changing technologies and extensive competition
in genomic sequencing; unanticipated increases in costs or
expenses; interruptions or delays in the supply of components or
materials for, or manufacturing of, PacBio products and products
under development; potential product performance and quality issues
and potential delays in development timelines; the possible loss of
key suppliers; and, third-party claims alleging infringement of
patents and proprietary rights or seeking to invalidate PacBio's
patents or proprietary rights. Additional factors that could
materially affect actual results can be found in PacBio's most
recent filings with the Securities and Exchange Commission,
including PacBio's most recent reports on Forms 8-K, 10-K, and
10-Q, and include those listed under the caption "Risk Factors."
These forward-looking statements are based on current expectations
and speak only as of the date hereof; except as required by law,
PacBio disclaims any obligation to revise or update these
forward-looking statements to reflect events or circumstances in
the future, even if new information becomes available.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-announces-kinnex-rna-kits-further-scaling-hifi-sequencing-in-full-length-rna-single-cell-rna-and-16s-rrna-applications-301972227.html
SOURCE Pacific Biosciences of California, Inc.